Affiliation:
1. Staten Island University Hospital, Staten Island, NY 10305, USA
2. University of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA
Abstract
Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to better characterize the progression-free survival (PFS) and overall survival (OS) in metastatic CRPC patients treated with PARPis. A systemic review search was conducted using National Clinical Trial (NCT), PubMed, Embase, Scopus, and Central Cochrane Registry. The improvement in overall survival was statistically significant, favoring PARPis (hazard ratio (HR) 0.855; 95% confidence interval (CI) 0.752–0.974; p = 0.018). The improvement in progression-free survival was also statistically significant, with results favoring PARPis (HR 0.626; 95%CI 0.566–0.692; p = 0.000). In a subgroup analysis, similar results were observed where the efficacy of PARPis was evaluated in a subgroup of patients without homologous recombination repair (HRR) gene mutation, which showed improvement in PFS favoring PARPis (HR 0.747; 95%CI 0.0.637–0.877; p = 0.000). Our meta-analysis of seven RCTs showed that PARPis significantly increased PFS and OS when used with or without antihormonal agents like abiraterone or enzalutamide.
Reference31 articles.
1. Prostate cancer;Rebello;Nat. Rev. Dis. Primers,2021
2. Epidemiology, Staging and Management of Prostate Cancer;Barsouk;Med. Sci.,2020
3. Reconsidering Prostate Cancer Mortality—The Future of PSA Screening;Welch;N. Engl. J. Med.,2020
4. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials;Niazi;Oncology,2021
5. Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: The key to move towards precision health in prostate cancer management;Ferraro;Clin. Chem. Lab. Med.,2023
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献